During 2018 Q4 the big money sentiment decreased to 1.08. That’s change of 0.68, from 2018Q3’s 1.76. 19 investors sold all, 46 reduced holdings as Spectrum Pharmaceuticals, Inc. ratio is negative. 51 increased stakes while 19 funds took stakes. Funds hold 82.09 million shares thus 3.65% less from 2018Q3’s 85.20 million shares.
Arizona State Retirement reported 156,413 shs. Point72 Asset Mgmt L P owns 539,200 shs. First Personal Fincl Svcs holds 0% or 370 shs in its capital. Arrowmark Colorado Ltd Liability Com has 0.27% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 2.98M shs. Quinn Opportunity Partners Limited Liability Corporation, a New York-based fund reported 18,000 shs. Trexquant Lp invested 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). State Street stated it has 5.86M shs or 0% of all its holdings. Fosun Limited has invested 0.06% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Tiaa Cref Inv Mgmt Llc has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 349,896 shs. 72,448 were accumulated by Susquehanna Interest Llp. Teachers Retirement Sys Of The State Of Kentucky holds 0% or 21,722 shs. Wells Fargo Mn holds 670,617 shs. Public Sector Pension Board has invested 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Fisher Asset Mngmt Limited Liability holds 0% or 180,663 shs in its capital. Alliancebernstein Lp invested in 163,675 shs or 0% of the stock.

Spectrum Pharmaceuticals, Inc. had 11 insider sales and 0 insider purchases since November 8, 2018. This’s net activity of $1.38 million. $53,135 worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was sold by Turgeon Joseph W.. 6,010 shs were sold by Vyas Dolatrai, worth $63,826 on Tuesday, January 22. Another trade for 2,496 shs valued at $27,541 was made by McGahan Keith M on Thursday, February 7. $366,333 worth of stock was sold by GUSTAFSON KURT A on Wednesday, January 9. Riga Thomas J sold $109,578 worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) on Wednesday, January 16.

Change of 13.65% for Spectrum Pharmaceuticals Inc (NASDAQ:SPPI)’s shorted shares was registered. FINRA announced in April SPPI’s total 8.42M shorted shares. That’s 13.65% up from 7.41 million shares. 10 days will cost SPPI with 848,600 average volume to recover its former position.

SPPI is touching $9.53 during the last trading session, after decreased 0.94%.Currently Spectrum Pharmaceuticals, Inc. is downtrending after 47.79% change in last April 18, 2018. SPPI has also 611,667 shares volume. SPPI underperformed the S&P 500 by 52.16%.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products.The firm is valued at $1.05 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin??s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.Last it reported negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

In total 4 analysts cover Spectrum Pharmaceuticals (NASDAQ:SPPI). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 7 are the (NASDAQ:SPPI)’s analyst reports since November 12, 2018 according to StockzIntelligence Inc. On Friday, March 1 the firm earned “Buy” rating by H.C. Wainwright. The stock rating was maintained by FBR Capital with “Buy” on Monday, November 12. On Friday, March 15 the firm has “Buy” rating given by Cantor Fitzgerald. On Friday, March 15 H.C. Wainwright maintained the shares of SPPI in report with “Buy” rating. On Friday, March 15 Jefferies initiated Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) with “Buy” rating. On Thursday, February 28 the firm has “Buy” rating given by Cantor Fitzgerald.

For more Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news released briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Spectrum submits BLA for Rolontis – Seeking Alpha” released on December 27, 2018, “Spectrum Pharmaceuticals (SPPI) Presents At H.C. Wainwright & Co. Annual Global Life Sciences Conference – Slideshow – Seeking Alpha” on April 09, 2019, “Spectrum Pharma Q4 top line up 3% – Seeking Alpha” with a publish date: March 01, 2019, “Why Is Spectrum Pharma (SPPI) Down 1.1% Since Last Earnings Report? – Nasdaq” and the last “Spectrum Pharmaceuticals (SPPI) To Presemt At Oppenheimer 29th Annual Healthcare Conference – Slideshow – Seeking Alpha” with publication date: March 21, 2019.